Navigation Links
Dermatophytic Onychomycosis Therapeutics Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020
Date:8/23/2014

Albany, New York (PRWEB) August 23, 2014

Dermatophytic onychomycosis also referred to as ringworm of the nail is one of the most common fungal infections of the nails. This infection results in the change in appearance of the nails such as, increased opaqueness and whitening along with increased thickening and fragility. Tinea unguium specifically describes the dermatophytic invasion of the nail plates and is the most common in cases when an artificial nail is applied as the nails are abraded with the help of an emery board and these boards have a probability of carrying infection and also water collection under the nail results in creation of moist and warm environment favorable for fungal growth. Toenails are more commonly affected than finger nails. Onychomycosis infections accounts for one third of fungal skin infections and the diagnosis can be facilitated with the help of direct microscopy imaging of potassium hydroxide preparation or culture before opting for the treatment of the infection. The occurrence of this infection is more common in the adults aged 50 years and above.

This infection can lead to serious health conditions such as it can decrease the peripheral circulation and would result in the conditions such as diabetic foot ulcers, and venous stasis. There are three main classes of organisms that cause onychomycosis namely, dermatophytes (fungi), nondermatophyte molds and yeast. Infection resulting from all these three classes of organisms cause similar symptoms along with similar visual appearance. Dermatophytes such as Microsporum, Epidermophyton and Trichophyton species are the most common dermatophytes responsible for infection and are the most common cause of onychomycosis worldwide. Whereas nondermatophyte molds and yeasts are less common causes of infection accounting for around 2% and 8% of the total onychomycosis infections.

Browse Dermatophytic Onychomycosis Therapeutics Market Report: http://www.transparencymarketresearch.com/dermatophytic-onychomycosis-therapeutics.html.

The five major subtypes of onychomycosis are as follows:

  • White superficial onychomycosis (WSO)
  • Candidal onychomycosis
  • Distal lateral subungual onychomycosis (DLSO)
  • Proximal subungual onychomycosis (PSO)
  • Endonyx onychomycosis

Patients may suffer from a combination of three subtypes of infection and the features of these sub types vary from each other. Topical and oral medications are administered for treatment of onychomycosis infections. Topical medications includes the use of Ciclopirox olamine 8% nail lacquer solution, Amorolfine or bifonazole while oral medications includes the use of Itraconazole, Terbinafine and Flucanazole. Also there are certain non-pharmacological treatments such as photodynamic therapy, laser treatment, and mechanical chemical or surgical nail avulsion.

Dermatophytic onychomycosis infection therapeutics market can be segmented on the basis of various treatment options available such pharmacological and non-pharmacological treatment options. Further these segments can be categorized on the basis of types of the treatment available such as oral medications or drugs and topical medications. Also, a detailed geographical landscape elucidating the market trends for four major geographies such as North America, Europe, Asia-Pacific and RoW can be provided. In addition, an analysis of key events influencing the market trends and detailed vendor landscape of the market can also be provided.

Some of the major factors influencing the market growth are consistent rise in the prevalence of onychomycosis infections worldwide along with development of novel medications available commercially for the treatment of onychomycosis infections. In addition, consistent rise in geriatric population who are highly susceptible for acquiring the infections along with rise in treatment rate owing to increasing socialization of the individuals are some of the factors that would further drive the dermatophytic onychomycosis infections therapeutics market. On the other hand, increased circulation of off label products and negligence towards this infection especially in less developed economies would impede the market growth. Some of the key players operating in the Dermatophytic Onychomycosis Therapeutics market are Janssen Biotech, Novartis International AG, Pfizer, Inc. and Anacor pharmaceuticals, Inc.

This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. This report provides comprehensive analysis of:

  • Market growth drivers
  • Factors limiting market growth
  • Current market trends
  • Market structure
  • Market projections for upcoming years

Early buyers will receive 10% customization on this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2871.

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Reasons for Buying this Report

  • This report provides pin-point analysis for changing competitive dynamics
  • It provides a forward looking perspective on different factors driving or restraining market growth
  • It provides a six-year forecast assessed on the basis of how the market is predicted to grow
  • It helps in understanding the key product segments and their future
  • It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
  • It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
  • It provides distinctive graphics and exemplified SWOT analysis of major market segments

Contact:
Sheela AK
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA/Canada Toll Free: 866-552-3453
Email: sales(at)transparencymarketresearch(dot)com
Web: http://www.transparencymarketresearch.com/
Blog: http://www.tmrblog.com/

Read the full story at http://www.prweb.com/releases/2014/08/prweb12114504.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Global Dermatophytic Onychomycosis Therapeutics Market 2012 - 2016: Worldwide Industry Latest Market Share, Growth, Size, Trends, Strategy And Forecast Research Report
2. Body Oasis Laser Aesthetics Medi Spa Acquires Noveon Nailaser for Treatment of Onychomycosis
3. Cardiomyopathy (Heart Muscle Disease) Therapeutics Clinical Trials Market 2014 Analysis in a New Report Available at MarketOptimizer.org
4. Critical Care Therapeutics in Major Developed Markets to 2020
5. Researchmoz
6. Global Antifungal Therapeutics Market 2014 Trends and Opportunities New Study Now Available at MarketReportsOnline.com
7. Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com
8. Multiple Sclerosis Therapeutics Clinical Trials Market Review H2 2014 Analysis Report Available at MarketOptimizer.org
9. Global Hospital Infection Therapeutics Market: Industry Analysis, Size, Share, Growth and Forecast- 2018
10. Global Epilepsy Therapeutics Market: Industry Analysis, Size, Share, Growth and Forecast 2019
11. A*STAR partners Roche to develop new cancer therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 2016 , ... Experts from the American Institutes for Research ... June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR experts ... planning, healthcare costs and patient and family engagement. , AIR researchers will be ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Conventional wisdom ... of success. In terms of the latter, setting the bar too high can result ... more than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
(Date:6/23/2016)...  In a startling report released today, National Safety Council ... a comprehensive, proven plan to eliminate prescription opioid overdoses. ... states are tackling the worst drug crisis in recorded U.S. history, ... Kentucky , New Mexico , ... the 28 failing states, three – Michigan , ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: